DNA replication

FERROFECT® Helps Address Anemia

Retrieved on: 
Wednesday, March 27, 2024
Pregnancy, Health, Absorption, Adenosine triphosphate, DNA replication, Cell, Zinc, DNA, Copper, Pharmacist, Quality of life, Woman, Supplement, Oxygen, ATP, WHO, Anemia, Iron, Digestion, Dietary supplement

FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- The body uses iron for many functions. Most of this iron is obtained through an individual's diet. However, when there is a chronic shortage of iron or the body struggles to synthesize it, it can be a problem. This can lead to iron deficiencies and anemia (the under-production of red blood cells, often due to a lack of iron). Three million Americans suffer from anemia, and WHO estimates that the condition globally impacts half a billion women and over a quarter of a billion children under the age of five.

Key Points: 
  • This can lead to iron deficiencies and anemia (the under-production of red blood cells, often due to a lack of iron).
  • Three million Americans suffer from anemia, and WHO estimates that the condition globally impacts half a billion women and over a quarter of a billion children under the age of five.
  • In addition, FERROFECT® helps with the production of adenosine triphosphate (ATP).
  • FERROFECT® even helps with DNA replication , a critical function required for cells to split and grow.

Korea University Study Explores a Novel and Precise Mitochondrial Gene Editing Method

Retrieved on: 
Friday, February 23, 2024
Toxicity, Gene editing, File association, DSM-IV codes, DNA replication, Cell, RNA, Associate, Genome, A-DNA, Issue 1, Research, DNA, Mouse, Korea University, Vaccine

Targeted base editing of mammalian mtDNA is a powerful technology for modeling mitochondrial genetic diseases and developing potential therapies.

Key Points: 
  • Targeted base editing of mammalian mtDNA is a powerful technology for modeling mitochondrial genetic diseases and developing potential therapies.
  • Programmable deaminases, which consist of a custom DNA-binding protein and a nucleobase deaminase, enable precise mtDNA editing.
  • Prof. Lee's research hints at a potential future in which the mitochondrial gene editing technology gains similar recognition.
  • The achievement of correcting mitochondrial A-to-G in mice not only highlights the efficacy of the novel gene editing method but also signals a significant step toward developing approved treatments for mitochondrial genetic diseases.

New Tool Reveals Gene Behavior in Bacteria

Retrieved on: 
Wednesday, January 24, 2024
Death, ECG, DNA replication, Alfred P. Sloan Foundation, TRIPS Agreement, Heart, DNA, Ralph, Champaign–Urbana metropolitan area, Publishing, Gene, University, Medicine, Genetics, Environment, Tick, In situ hybridization, Bacteria, NYU, Human, Cell cycle, Disease, NYU Langone Health, Protein, Nature, Doctor of Philosophy, Genome, National Institutes of Health, Messenger, Gene expression, Bangladesh Technical Education Board, Pathogenic bacteria, TRIP, Cell, Vaccine

This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.

Key Points: 
  • This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.
  • According to the study authors, organisms from bacteria to humans grow as their cells multiply by dividing, with each cell becoming two.
  • Specifically, the research team found that when DNA polymerase arrives at any specific gene, it disrupts the transcription in a way that reveals the state of that gene's regulatory status.
  • Ultimately, they believe that improvements in technology will enable them to dive ever deeper into gene behaviors in different bacterial species.

Global CDC7 Kinase Inhibitors Clinical Trials & Market Insight Report 2024 Featuring Carna Biosciences, Chia Tai Tianqing Pharma, Eli Lilly, Memorial Sloan-Kettering Cancer Center, and Schrodinger - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 11, 2024
Health, Oncology, Clinical Trials, Other Health, DNA virus, Cell division, Patient, Mitosis, Indication, DNA replication, Research, Viral, Radiation, DNA, S phase, DNA repair, DBF4, Cancer, Cell proliferation, CDC7, Cell death, Virus, Inflammation, VP3

The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types.
  • In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.
  • Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, December 6, 2023
Blood, PAM, Breast cancer, Cell, Gedatolisib, DNA, Cell proliferation, AKT, CELC, Poster, Publication, DNA replication

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • The preclinical studies evaluated gedatolisib, a pan-PI3K/mTOR inhibitor, and PAM inhibitors that selectively target single PAM nodes (PI3Kα, AKT, and mTORC1) to compare the functional effect of inhibiting multiple vs. single PAM pathway nodes in a panel of breast cancer cell lines.
  • In cell viability and proliferation analyses, gedatolisib was found to be more cytotoxic and at least 300-fold more potent, on average, compared to the single node PAM inhibitors.
  • Mechanistically, gedatolisib decreased cell survival, DNA replication, protein synthesis, glucose consumption, lactate production and oxygen consumption more effectively than the other PAM inhibitors.

Laureates of the 2023 WLA Prize Announced

Retrieved on: 
Thursday, September 14, 2023
DNA, Operation, Mathematics, DNA condensation, Georgia Tech, Emeritus, System, H. Milton Stewart School of Industrial and Systems Engineering, Crystallography, ETH, Prize, Chromatin, MRC Laboratory of Molecular Biology, WLA, Georgia Institute of Technology School of Computer Science, Research, International Journal of Biological Macromolecules, History, RMB, DNA replication, Machine learning, Algorithm, Engineering, Nucleosome, Computer science, Economics, Pharmaceutical industry, Management, Medical imaging, Microscope, Nesterov, Chemistry, Medicine, Physiology

Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.

Key Points: 
  • Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, John P. Hunter, Jr.
  • The 2023 WLA Prize Award Ceremony is scheduled to take place in Shanghai on November 6, followed by a series of engaging sessions to celebrate the laureates' outstanding achievements.
  • The WLA Prize is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA), managed by the WLA Foundation, and exclusively funded by HongShan.

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Retrieved on: 
Thursday, August 10, 2023
Insurance, APRE, DNA, IPR, Pharmacia, DDR, Renã A. S. Robinson, Drug discovery, Clinical trial, Pharmacokinetics, G&A, Research, WEE1, Research and development, DNA replication, Acquisition, DNA repair, Novartis, Administration, Cell cycle, R, Sanofi, Therapy, Safety, IND, ATR, Mammography, Fine chemical, Pharmaceutical industry, Cryptocurrency, Life insurance, Aprea-Cuccaro clan, Pfizer

DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30, 2023 and provided a business update.
  • The Company expects to report initial interim safety, tolerability, and pharmacokinetic data from the ongoing Phase 1 trial of ATRN-119 in the fourth quarter of 2023.
  • Select Financial Results for the Second Quarter ended June 30, 2023
    As of June 30, 2023, the Company reported cash and cash equivalents of $27.7 million.
  • General and Administrative (G&A) expenses were $1.7 million for the quarter ended June 30, 2023, compared to $15.6 million for the same period in 2022.

City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

Retrieved on: 
Tuesday, August 1, 2023
Linda, Molecule, Alex's Lemonade Stand Foundation, DNA, Rituximab, Insulin, Human, City of Hope National Medical Center, City of Hope, R01, Neoplasm, Biotechnology, Cell Chemical Biology, Trastuzumab, Clinical trial, Ovary, Breast, Toxicity, Brain, Research, Gene expression, Prostate, Treatment of lung cancer, Cell, Molecular diagnostics, Translational Genomics Research Institute, Cetuximab, Experiment, RLL, Bangladesh Technical Education Board, DNA replication, National Cancer Institute, S phase, Australian Melanoma Research Foundation, Patient, Department of Defense Serum Repository, Apoptosis, LOS, Beckman Research Institute, Proliferating cell nuclear antigen, Therapy, Skin, PCNA, Vaccine, Pharmaceutical industry, Molecular oncology, City, Hope

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. As the scientists continue to investigate the foundational mechanisms that make this cancer-stopping pill work in animal models, they note that there is an ongoing Phase 1 clinical trial testing the City of Hope-developed therapeutic in humans.

Key Points: 
  • Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.
  • The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope."
  • Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines."
  • "City of Hope has world leaders in cancer research.

Global Doxorubicin Market Report 2023: Growing Demand for Effective Cancer Treatments Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutical, Health, Oncology, Doxorubicin, DNA, Streptomyces, Cell death, Hair loss, Multiple myeloma, Bone marrow suppression, Cancer, Lung cancer, Bladder cancer, Immunotherapy, Cardiotoxicity, USD, Vomiting, DNA replication, Stomach cancer, Incidence, Anthracycline, Patient, Risk, B-cell lymphoma, Hodgkin lymphoma, Nausea, Growth, Ovarian cancer, Thyroid cancer, Breast cancer, Mouth ulcer, Extrusion, Pharmaceutical industry

The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global doxorubicin market size attained a value of USD 1218 million in 2022.
  • [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments.

Investigating the placenta: Discovery from Stowers Scientists shows why this often-overlooked organ should be given more attention

Retrieved on: 
Wednesday, June 7, 2023
Dai, DNA, Human, Pregnancy, Placenta, Mortal Kombat, Stowers Institute for Medical Research, Fetus, Parent, Embryo, Indira Gandhi Institute of Development Research, Research, Attention, Polyploidy, Cell, DNA replication, Chromosome, Place of birth, Preterm birth, Immune system, Pre-eclampsia, Cell cycle, Mouse, Placentalia, Birth, Medical research, Genome, Disease, Dietary supplement, Baking, Birth control, Vaccine, Development

"I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."

Key Points: 
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."
  • "Following birth, the placenta is often tossed in the medical wastebin," explained Stowers Investigator Jennifer Gerton, Ph.D. "This makes it the most overlooked, undervalued, and understudied organ in reproductive science."
  • "The placenta may be the most polyploid organ in a pregnant female mouse, but more research into polyploidy is warranted."
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."